Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

In the U.S., receiving healthcare depends on information changing hands. And that’s not just for patients undergoing ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

It took several attempts and much debate, but on Friday, the Centers for Disease Control and Prevention's (CDC’s) newly ...

Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...

After many months of uncertainty related to the Biosecure Act and associated security efforts in Washington, D.C., Chinese ...

Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from ...

With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy ...

President Donald Trump has been successful in convincing many of the world’s top drugmakers to commit to manufacturing more ...

The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to ...

Uncertainty reigned early this year with the inauguration of President Donald Trump and his threats to impose tariffs and ...